Company: NDRA
Filing Date: 2025-07-16
Form Type: S-1/A
Source: 0001654954-25-008117
Chunk: 3

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-07-16
Form: S-1/A
Chunk 3
---
 prospectus is $8.07 (equal to the last sale price of our common stock as reported by The Nasdaq Capital Market on July 15, 2025). The actual public offering price per each share of common stock or Pre-Funded Warrant in this offering will be determined between us and the Underwriter (defined below) at the time of pricing and may reflect a discount to the current market price for our common stock. Therefore, the recent market price used throughout this preliminary prospectus as a basis for an assumed public offering price per share of common stock may not be indicative of the final public offering price.

We have engaged Lucid Capital Markets, LLC (the “Underwriter”) to act as our exclusive underwriter in connection with this offering. We have agreed to pay to the Underwriter the fees set forth in the table below. We will bear all costs associated with the offering. See “Underwriting” on page 35 of this prospectus for more information regarding these arrangements.

We will have one closing for all the securities purchased in this offering. The public offering price per share of common stock will be fixed for the duration of this offering.

|                                      |     | Per share |     | Per Pre-Funded Warrant |     | Total |
|:-------------------------------------|:----|:----------|:----|:-----------------------|:----|:------|
| Public offering price                |     | $         |     | $                      |     | $     |
| Underwriter fees (1)                 |     | $         |     | $                      |     | $     |
| Proceeds, before expenses, to us (2) |     | $         |     | $                      |     | $     |

____________

| (1) | We have agreed to pay the Underwriter a cash fee equal to 7.0% of the gross proceeds of this offering up to $100 million and 5.0% of any gross proceeds in this offering in excess of $100 million. This does not include the reimbursement of certain expenses of the Underwriter we have agreed to pay. We have also agreed to issue the Underwriter, or its designees, warrants to purchase a number of shares of common stock equal to 4.0% of the number of shares of common stock and Pre-Funded Warrants issued in this offering See “Plan of Distribution” for additional disclosure regarding the compensation to be received by the Underwriter. |
| (2) | The amount of the offering proceeds to us